Sector News

The top 15 generic drugmakers by 2016 revenue

May 16, 2017
Life sciences

Branded drugmakers weren’t the only ones working through a tumultuous 2016. Generics companies faced pricing pressure, too.

And while branded companies suffer pricing pain on costly cutting-edge therapies, generics outfits feel the pinch with already-thin margins, making pressure all the more agonizing.

> Read the full article on the Fierce Pharma website

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

October 1, 2023

Clinical data from Boston Scientific and rivals could reshape pulmonary embolism market: analysts

Life sciences

After attending the annual Pulmonary Embolism Symposium last week in Austin, Texas, the analysts predicted clinical guidelines could shift toward catheter-based therapy once data from ongoing randomized trials is available.

October 1, 2023

AstraZeneca and SAS link up on AI and analytics

Life sciences

SAS – the AI and analytics company – has been selected by AstraZeneca to help boost efficiency and drive automation in the delivery of statistical analyses for clinical and post-approval submissions to regulatory authorities.

October 1, 2023

Will Big Pharma engage in Medicare price negotiations? Merck, AZ and BMS say they will

Life sciences

After the Centers for Medicare & Medicaid Services (CMS) revealed the list of drugs set to face the first round of price negotiations under the Inflation Reduction Act (IRA), the drugmakers responsible for marketing them are confronting a series of deadlines.

How can we help you?

We're easy to reach